Cargando…

A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma

LESSONS LEARNED. Clofarabine can be active in relapsed and refractory lymphoid malignancies on a weekly dosing schedule. Responses were seen in patients with T‐cell lymphomas, including cutaneous T‐cell lymphoma, but not in patients with aggressive B‐cell lymphomas. BACKGROUND. Clofarabine is a seco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foss, Francine Marie, Parker, Terri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2018
Materias:	Clinical Trial Results
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896711/ https://www.ncbi.nlm.nih.gov/pubmed/29438091 http://dx.doi.org/10.1634/theoncologist.2017-0658

Ejemplares similares

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
por: Johnson, Melissa L, et al.
Publicado: (2023)

Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
por: Cao, Junning, et al.
Publicado: (2017)

Efficacy of Low Dose Clofarabine in Refractory Precursor T- Acute Lymphoblastic Leukemia
por: Choi, Jaehyuk, et al.
Publicado: (2007)

Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)
por: Ostwal, Vikas, et al.
Publicado: (2022)

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
por: Bendell, Johanna C., et al.
Publicado: (2018)

Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors
por: Wheler, Jennifer, et al.
Publicado: (2017)

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017)

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
por: Jin, Ning, et al.
Publicado: (2016)

A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
por: Lieu, Christopher H., et al.
Publicado: (2017)

Cladribine with Granulocyte Colony‐Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study
por: Wang, Hua, et al.
Publicado: (2020)

E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors
por: Lubner, Sam, et al.
Publicado: (2018)

An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma
por: El Dika, Imane, et al.
Publicado: (2018)

Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma
por: Kazandjian, Dickran, et al.
Publicado: (2021)

A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer
por: Davis, S. Lindsey, et al.
Publicado: (2018)

A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)
por: Chu, Li, et al.
Publicado: (2021)

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
por: Chiappori, Alberto A., et al.
Publicado: (2016)

A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
por: Chen, Xiaofeng, et al.
Publicado: (2019)

S‐1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial
por: Chen, Ye, et al.
Publicado: (2019)

A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
por: Segar, Jennifer M., et al.
Publicado: (2019)

Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study
por: Ollila, Thomas, et al.
Publicado: (2022)

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma
por: Tella, Sri Harsha, et al.
Publicado: (2023)

A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer
por: Liu, Jian, et al.
Publicado: (2016)

Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy
por: Flinn, Ian W., et al.
Publicado: (2019)

Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results
por: Passardi, Alessandro, et al.
Publicado: (2017)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer
por: Wei, Xiao X., et al.
Publicado: (2018)

Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
por: Satake, Hironaga, et al.
Publicado: (2020)

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia
por: Tse, Eric, et al.
Publicado: (2011)

Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study
por: Sakurada, Takumi, et al.
Publicado: (2022)

A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study
por: Riedel, Richard F., et al.
Publicado: (2020)

Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)
por: Sideras, Kostandinos, et al.
Publicado: (2022)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma
por: Li, Haoran, et al.
Publicado: (2023)

Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study
por: Labots, Mariette, et al.
Publicado: (2018)

Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study
por: Lipplaa, Astrid, et al.
Publicado: (2023)

A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
por: Lolli, Cristian, et al.
Publicado: (2017)

Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer
por: Siano, Marco, et al.
Publicado: (2017)

Endostatin and Oxaliplatin‐Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study
por: Li, Wenxin, et al.
Publicado: (2019)

A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
por: Burotto, Mauricio, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ol3hofnnjngb5vf0j4qj4c0fmv